Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Five Arrows invests in Sygnature Discovery

Sygnature Discovery has received a significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co. Financial details have not been disclosed.

Sygnature’s existing private equity investor, Phoenix Equity Partners, is exiting as a shareholder, having supported the company since September 2017. Since Phoenix invested, Sygnature’s annual revenue has more than doubled and the number of employees has increased from 200 to 450. This impressive growth has been driven both organically and via strategic acquisitions.

Sygnature’s CEO Simon Hirst said: “We are delighted to have Five Arrows as our chosen investor. Five Arrows has a strong track record in supporting healthcare companies to grow through organic means as well as through acquisition. They have, through Rothschild & Co, a unique and unrivalled platform for supporting their investee companies. With their support, we remain committed to being at the forefront of scientific innovation in drug discovery and to provide the highest quality of service to our rapidly expanding global client base.”

Sacha Oshry, Managing Director at Five Arrows remarked: “We are thrilled to partner with Sygnature for the next phase of its journey. We greatly like the company’s science-driven ethos and unrelenting focus on customer service which together have established Sygnature as a global research partner of choice. We believe that Sygnature represents an exceptional platform in the drug discovery space and is well primed to capitalise on its position in the most attractive and growing segments of the sector. We look forward to working with Simon and his team to help the business achieve its full potential over the coming years.”

Kevin Keck and Barry Robinson, Partners at Phoenix, commented: “It has been a pleasure to partner with the Sygnature team and to support the company’s strong track record of growth. Sygnature is an exceptional business with a fantastic culture, committed to providing a world-class service to its clients. We have no doubt that Sygnature will continue to prosper, and we wish the management team and Five Arrows every success in the years to come.”

The Corporate Finance Advisory team at Deloitte in the Midlands acted as exclusive lead financial advisors, with Deloitte also providing tax advice. Legal advice was provided by Eversheds Sutherland in Nottingham. Alantra acted as exclusive financial adviser to Five Arrows and Shoosmiths acted as legal advisor.

Latest News

View All

Five Arrows invests in Sygnature Discovery

Sygnature Discovery expands into early CMC development

Sygnature gains ISO:27001 certification for information security

Sygnature appoints Dr David Lustig to spearhead…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.